RECEIVED
CENTRAL FAX CENTER
SEP 0 8 2006

CURRENT LISTING OF CLAIMS

1. **(currently amended)** A compound according to formula **I**



(I)

wherein ~~(i) R^1, R^2 and R^3 are independently selected from the group consisting of hydrogen, C_{1-10} acyl, C_{1-10} alkoxycarbonyl; or, (ii)~~ R^1 is COR^4 where COR^4 is the hydrochloride salt of an amino acid or a dipeptide and R^2 and R^3 are independently hydrogen, C_{1-10} acyl, or C_{1-10} alkoxycarbonyl ; and, hydrates, solvates, clathrates thereof~~, with the proviso that at least one of R^1, R^2 and R^3 is not hydrogen~~.

2. **(original)** A compound according to claim 1 wherein R^1 is COR^4, and R^4 is $CH(R^5)NH_3^+$ Cl or pyrrolidin-2-yl, R^5 is selected from the group consisting of $CH(CH_3)_2$ and $CH(CH_3)CH_2CH_3$, and both R^2 and R^3 are hydrogen.

3-8. **(canceled)**

9. **(original)** A method for modulating Th1 and Th2 immune activity comprising administering to a mammal a therapeutically effective amount of a compound according to Claim 1.

10. **(original)** A method according to claim 9 wherein R^1 is COR^4, and R^4 is $CH(R^5)NH_3^+$ Cl^- or pyrrolidin-2-yl, R^5 is $CH(CH_3)_2$ or $CH(CH_3)CH_2CH_3$, and both R^2 and R^3 are hydrogen.

11. **(original)**A method according to claim 9 wherein R^1 is COR^4, and R^4 is $CH(R^5)NH_3^+$ Cl, R^5 is CH_3, and both R^2 and R^3 are hydrogen.

12. **(canceled)**

13. (original) The method of Claim 9 wherein the compound is delivered in a dose of between 0.1 and 300 mg/kg of body weight of the patient/day.

14. (original) The method of Claim 9 wherein the compound is delivered in a dose of between 1.0 and 100 mg/kg of body weight of the patient/day.

15. (original) The method of Claim 9 wherein the compound is delivered in a dose of between 1.0 and 50 mg/kg of body weight of the patient/day.

16. (original) The method of claim 9 wherein the mammal is a human.

17. (original) The method of Claim 9 further comprising at least one other immune system modulator.

18. **(original)** The method of Claim 17 wherein the immune system modulator is an interferon or chemically-derivatized interferon.

19. **(original)** The method of claim 18 wherein the chemically derivatized interferon is PEG-interferon-α-2a (PEGASYS®) or PEG-interferon-α-2b (PEG-INTRON™)

20. **(original)** The method of Claim 9 further comprising a administering at least one other antiviral, antiparasitic or anticancer compound.

21. **(original)** A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and at least one pharmaceutically acceptable carrier and optionally containing excipients.

22. **(original)** A pharmaceutical composition according to claim 21 wherein R^1 is COR^4, and R^4 is $CH(R^5)NH_3^+ Cl^-$, R^5 is $CH(CH_3)_2$, $CH(CH_3)CH_2CH_3$ or CH_3, and both R^2 and R^3 are hydrogen.

* * * * * * * * *